Overview

A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women

Status:
Completed

Trial end date:
2001-07-01

Target enrollment:

Participant gender:

Summary

This is a single center, open-label, randomized, parallel group, dose finding study to evaluate safety and efficacy of recombinant human luteinizing hormone (r-hLH, LHadi®), compared with urinary human chorionic gonadotrophin (u-hCG, Profasi®), both given subcutaneously, in inducing ovulation in infertile women undergoing stimulation of follicular growth with recombinant human follicle stimulating hormone (r-hFSH, Gonal-F®).

Phase:

Phase 2

Details

Lead Sponsor:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Chorionic Gonadotropin
Follicle Stimulating Hormone
Hormones